Review of clinical and real-world evidence comparing a subcutaneous autoinjector to IV dosing for anti-amyloid Alzheimer's therapy.
Key Takeaways
- Once-weekly 500 mg subcutaneous autoinjector showed bioequivalence with 104% exposure ratio
- ARIA-E incidence correlated with drug exposure rather than administration route
- Real-world series showed slower CDR-SB decline and 91% MMSE stability or improvement